Trials / Completed
CompletedNCT00912691
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Curemark · Industry
- Sex
- All
- Age
- 9 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.
Detailed description
Autism is currently a significant cause of disability in the pediatric population. CM-AT is based upon the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a powder taken three times a day. It is formulated to be released in the small intestine to enhance protein digestion thus increasing the availability of essential amino acids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM-AT | Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2009-06-03
- Last updated
- 2019-03-01
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00912691. Inclusion in this directory is not an endorsement.